What You Should Know:
– OM1 introduces three new products: OM1 Orion, OM1 Lyra, and OM1 Polaris powered by PhenOMTM – an artificial intelligence-powered digital phenotyping platform for personalized medicine and clinical research.
– OM1 is the leader in providing Real-World Evidence (RWE) insights from bench to bedside, leveraging advanced predictive and generative AI platforms coupled with deep clinical data to empower healthcare stakeholders.
Revolutionizing Healthcare with AI-Powered Solutions: OM1 PhenOM’s Impact on Patient Care and Research
In today’s healthcare landscape, disparate data sources create critical knowledge gaps from research and development to clinical decision-making. OM1 PhenOM stands out as a leader in innovative AI-powered solutions, addressing these challenges by providing insights that empower healthcare providers (HCPs) at the point of care, bridging gaps in patient journeys, and facilitating research and treatment for hard-to-find patient populations.
PhenOM, launched last year, leverages OM1’s high-quality data cloud, comprising billions of data points from over 340 million patients. This platform improves individual care and population health by offering distinct product lines that integrate next-gen AI technology and clinically robust real-world data. Here’s how PhenOM tackles key pain points across the healthcare ecosystem:
1. OM1 Orion: This solution caters to pharmaceutical decision-makers, offering a comprehensive view of the patient journey. By analyzing deep clinical data, OM1 Orion provides insights into disease progression and burden for specific patient sub-populations. It enables the discovery of unmet needs, identifies real-world drivers and barriers to care, and uncovers complex patterns in disease progression and treatment response. OM1 Orion significantly enhances research efficiency and reduces associated costs.
2. OM1 Lyra: Designed for clinicians and patients, OM1 Lyra generates personalized insights to guide treatment decisions. By predicting diagnosis, treatment options, and risk, Lyra facilitates personalized medicine at the point of care. It translates population-level patterns into actionable insights tailored to individual patients, placing their uniqueness at the forefront of treatment strategies.
3. OM1 Polaris: This solution optimizes clinical trial recruitment by leveraging real-world data and tailored phenotypic profiles. By predicting outcomes and identifying prospective patients, investigators, and sites, Polaris streamlines recruitment timelines, reduces costs, and increases the likelihood of trial success.
OM1 is a pioneer in healthcare innovation, specializing in personalized medicine, evidence generation, and real-world evidence research. Their insights-driven technology, powered by next-generation AI platforms and regulatory-grade deep longitudinal data, is backed by globally recognized thought leadership.
“There is a tremendous untapped opportunity to synthesize data sources to better understand patient journeys and treatment decisions, which we’ve learned to address with our digital phenotyping technology,” said Joseph Zabinski, VP, Head of Commercial Strategy & AI at OM1. “Now, with our expanded product offerings, we can identify patients to reveal hidden characteristics and predict outcomes, ultimately improving how we conduct research and deliver care.”
